WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
1. (WO2012091137) GENE THERAPEUTIC AGENT USING TNF-α, CD40L, AND GM-CSF IN COMBINATION
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2012/091137 International Application No.: PCT/JP2011/080515
Publication Date: 05.07.2012 International Filing Date: 28.12.2011
IPC:
A61K 48/00 (2006.01) ,A61K 9/127 (2006.01) ,A61K 31/7088 (2006.01) ,A61K 38/00 (2006.01) ,A61K 47/34 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
10
Dispersions; Emulsions
127
Liposomes
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
34
Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants: NAKANO, Kenji[JP/JP]; JP (UsOnly)
KATAOKA, Kazunori[JP/JP]; JP (UsOnly)
NISHIYAMA, Nobuhiro[JP/JP]; JP (UsOnly)
THE UNIVERSITY OF TOKYO[JP/JP]; 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 1138654, JP (AllExceptUS)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION[JP/JP]; 6-10-1 Hakozaki, Higashi-ku, Fukuoka-shi, Fukuoka 8128581, JP (AllExceptUS)
Inventors: NAKANO, Kenji; JP
KATAOKA, Kazunori; JP
NISHIYAMA, Nobuhiro; JP
Agent: TAKASHIMA, Hajime; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044, JP
Priority Data:
2010-29403528.12.2010JP
Title (EN) GENE THERAPEUTIC AGENT USING TNF-α, CD40L, AND GM-CSF IN COMBINATION
(FR) AGENT DE THÉRAPIE GÉNIQUE UTILISANT UNE COMBINAISON DE TNF-α, CD40L ET GM-CSF
(JA) TNF-α、CD40L及びGM-CSF併用遺伝子治療剤
Abstract:
(EN) The purpose of the invention is to provide a method for improving an increase in regulatory T-cells and a humoral immunity dominant immune status in immunotherapy-resistant intractable cancer without causing an adverse event of an autoimmune disease. The invention provides a pharmaceutical composition comprising a pharmaceutical composition (1) containing an expression vector for TNF-α as an active ingredient and a pharmaceutical composition (2) containing CD40L and GM-CSF as active ingredients in combination.
(FR) La présente invention a pour objet un procédé d'amélioration d'une augmentation de la teneur en cellules T régulatrices et d'une amélioration du statut immunitaire dominant en humidité humorale dans un cancer intraitable résistant à l'immunothérapie sans provoquer les effets secondaires indésirables d'une maladie auto-immune. La présente invention concerne une composition pharmaceutique comprenant une composition pharmaceutique (1) incluant un vecteur d'expression de TNF-α au titre de principe actif et une composition pharmaceutique (2) incluant CD40L et GM-CSF au titre de combinaison de principes actifs.
(JA)  本発明は、免疫療法に抵抗性を示す難治性癌における制御性T細胞の増加と液性免疫優位の免疫状態を改善することを、自己免疫疾患という有害事象を起こさず達成する方法を提供することを目的とする。本発明は、TNF-αの発現ベクターを有効成分として含有する医薬組成物(1)と、CD40L及びGM-CSFを有効成分として含有する医薬組成物(2)との組み合わせからなる医薬組成物を提供する。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)